Dirk Kersten
CIK: 0001823682
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Dyne Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (54 total)
- Jul 27, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect5.4K shares at avg. $26.04$140K - Jul 27, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect256.1K shares at avg. $25.50$6.5M - Jun 23, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect1.7K shares at avg. $21.47$36K - Jun 23, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect71.6K shares at avg. $21.04$1.5M - Jun 22, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect190.7K shares at avg. $20.57$3.9M - Jun 18, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect46.9K shares at avg. $20.07$941K - Jun 17, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect37.5K shares at avg. $20.14$754K - Jun 5, 2026DYN
Dyne Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
35.2K shares- - Apr 22, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect2.7K shares at avg. $20.00$53K - Apr 21, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect8.3K shares at avg. $20.01$166K - Apr 20, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect125.3K shares at avg. $20.07$2.5M - Apr 17, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect212K shares at avg. $20.29$4.3M - Apr 16, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect11.1K shares at avg. $21.10$235K - Apr 16, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect6.7K shares at avg. $20.06$134K - Apr 15, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect81.8K shares at avg. $20.27$1.7M - Mar 11, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect129.7K shares at avg. $19.52$2.5M - Mar 10, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect219.8K shares at avg. $19.32$4.2M - Mar 10, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect9.5K shares at avg. $18.21$173K - Mar 10, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect281.9K shares at avg. $19.80$5.6M - Mar 9, 2026DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect177.7K shares at avg. $17.72$3.1M - May 30, 2025DYN
Dyne Therapeutics, Inc.
Award(A)DirectStock option (right to buy)
35K shares- - Dec 9, 2024DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect34.4K shares at avg. $29.18$1.0M - Dec 6, 2024DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect101.7K shares at avg. $29.34$3.0M - Dec 5, 2024DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect3.8K shares at avg. $29.05$111K - Dec 4, 2024DYN
Dyne Therapeutics, Inc.
Sale(S)Indirect135K shares at avg. $29.39$4.0M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 27, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 5,388 | $26.04 | $140,319 | Indirect |
| Jul 27, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 256,072 | $25.50 | $6,530,451 | Indirect |
| Jun 23, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 1,657 | $21.47 | $35,583 | Indirect |
| Jun 23, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 71,629 | $21.04 | $1,506,766 | Indirect |
| Jun 22, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 190,676 | $20.57 | $3,922,263 | Indirect |
| Jun 18, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 46,901 | $20.07 | $941,373 | Indirect |
| Jun 17, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 37,454 | $20.14 | $754,316 | Indirect |
| Jun 5, 2026 | DYN Dyne Therapeutics, Inc. | Award(A) Stock option (right to buy) | 35,152 | - | - | Direct |
| Apr 22, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 2,652 | $20.00 | $53,049 | Indirect |
| Apr 21, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 8,300 | $20.01 | $166,120 | Indirect |
| Apr 20, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 125,274 | $20.07 | $2,513,898 | Indirect |
| Apr 17, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 211,974 | $20.29 | $4,301,292 | Indirect |
| Apr 16, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 11,116 | $21.10 | $234,591 | Indirect |
| Apr 16, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 6,657 | $20.06 | $133,523 | Indirect |
| Apr 15, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 81,840 | $20.27 | $1,659,044 | Indirect |
| Mar 11, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 129,672 | $19.52 | $2,530,562 | Indirect |
| Mar 10, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 219,758 | $19.32 | $4,246,823 | Indirect |
| Mar 10, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 9,482 | $18.21 | $172,687 | Indirect |
| Mar 10, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 281,858 | $19.80 | $5,580,817 | Indirect |
| Mar 9, 2026 | DYN Dyne Therapeutics, Inc. | Sale(S) | 177,690 | $17.72 | $3,148,987 | Indirect |
| May 30, 2025 | DYN Dyne Therapeutics, Inc. | Award(A) Stock option (right to buy) | 35,000 | - | - | Direct |
| Dec 9, 2024 | DYN Dyne Therapeutics, Inc. | Sale(S) | 34,437 | $29.18 | $1,004,872 | Indirect |
| Dec 6, 2024 | DYN Dyne Therapeutics, Inc. | Sale(S) | 101,675 | $29.34 | $2,983,145 | Indirect |
| Dec 5, 2024 | DYN Dyne Therapeutics, Inc. | Sale(S) | 3,806 | $29.05 | $110,564 | Indirect |
| Dec 4, 2024 | DYN Dyne Therapeutics, Inc. | Sale(S) | 135,039 | $29.39 | $3,968,796 | Indirect |
1-25 of 54 transactions
About Kersten Dirk
Kersten Dirk (SEC CIK 0001823682) files insider reports with the SEC as Director of Dyne Therapeutics, Inc. (DYN).
Signal8 holds 25 ownership filings by Kersten Dirk, all Form 4s, filed between Sep 4, 2024 and Jul 29, 2026. Those filings report 54 transactions, from Aug 30, 2024 to Jul 27, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kersten Dirk's filings is in WALTHAM, MA.
Recent filings by Kersten Dirk
- Jul 27, 2026: Open-market sales of DYN shares (2 lines, Form 4, code S).
- Jun 23, 2026: Open-market sales of DYN shares (2 lines, Form 4, code S).
- Jun 22, 2026: Open-market sale of DYN shares (Form 4, code S).
- Jun 18, 2026: Open-market sale of DYN shares (Form 4, code S).
- Jun 17, 2026: Open-market sale of DYN shares (Form 4, code S).
Other insiders filing for Dyne Therapeutics, Inc. (DYN)
- Kerr Douglas, Head of R&D and CMO
- Posner Brian S, Director
- Friedl-Naderer Johanna, Chief Commercial Officer
- Cox John, CEO & President
- Rhodes Jason P, Director
- Lucera Erick, Chief Financial Officer